

Chemicals business to grow at 20%+ in FY24E

SRF's Q4 headline performance was largely in-line however the composition varied with outperformance from Chemicals Business (CB) while Packaging Films Business (PFB) reported substantially muted performance. For FY23 too, robust CB margins led to 11.1% / 14.5% rise in YoY EBITDA/ PAT at Rs35.3bn/ Rs21.6bn while both PFB and Technical Textiles Business (TTB) deteriorated substantially. CB reported highest ever quarterly EBIT margins at 35.2% (FY23 average at 31.6%). However, management guided for some tapering of margins going ahead. Contrarily, PFB EBIT margins plummeted to the lowest ever quarterly at 3.6% (FY23 average at 10.7%). Management cited margins to remain under pressure in medium term however are expected to recover from hereon. SRF remained confident of robust 20%+ YoY growth in CB for FY24E propelled by scale up in existing projects and commercialisation of new projects. Based on management guidance, and better CB margins, we have upped our FY24E earnings estimates by 2.1% while lowering FY25E earnings by 4.0% considering margin normalisation. Since our last update the stock has moved up by ~18%. Rolling over our valuations to FY25E, using SOTP methodology, we downgrade the stock to Add with a revised TP of Rs2,895 (earlier Rs2,543).

CB margins at peak, PFB margins at nadir

CB drove overall Q4 performance with 19.6% QoQ surge in revenues coupled with highest ever EBIT margins at 35.2%. However, management cited that margins may taper going ahead and cautioning demand weakness for refgas in Q1FY24E. Contrarily, PFB faced strong headwinds with revenues declining 4.1% QoQ while EBIT margins plummeting to the lowest at 3.6%. Management guided margin recovery hereon however pressure to continue in medium term.

CB to drive momentum in FY24E, planning to enter pharma CDMO space

Despite substantial 41.4% YoY revenue growth in CB during FY23, management remained confident of 20%+ growth for FY24E. Company is witnessing growing demand for new products without any demand challenges from customers (80-85% innovators in CB). SRF is also working on a number of projects (7-8) for advanced intermediates with a good visibility of commercialisation over the next two years. Management also cited its plans to enter into pharma CDMO space through organic/ inorganic route.

PFB and TTB to remain subdued in near term

Weak demand coupled with capacity additions led to downfall in PFB margins which are expected to remain under pressure in near term. However, volumes may improve with debottlenecking in South Africa and Hungarian operations coming back to normalcy. TTB demand is recovering marginally.

CB margins peaked, while recovery expected in TTB/ PFB

Based on management guidance, we have upped CB EBIT margins while reducing PFB/ TTB margins for FY24E. The stock is trading at 30.7x/ 26.5x FY24E/ FY25E EPS of Rs83.8/ Rs97.0. We have valued SRF using SOTP methodology and downgrade our rating to ADD with a revised TP of Rs2,895 (earlier Rs2,543)

Risks – Sharp margin correction in CB, extended demand/ margin pressure in TTB/ PFB

Financial and valuation summary

YE Mar (Rs mn)	4QFY23A	4QFY22A	YoY (%)	3QFY23A	QoQ (%)	FY23A	FY24E	FY25E
Revenues	37,781	35,494	6.4	34,697	8.9	145,918	162,263	186,614
EBITDA	9,596	9,366	2.5	8,486	13.1	35,292	41,208	47,074
EBITDA margin (%)	25.4	26.4	(3.7)	24.5	3.9	23.7	25.3	25.1
Adj. Net profit	5,544	5,883	(5.8)	5,017	10.5	21,623	24,827	28,747
Adj. EPS (Rs)	18.7	19.8	(5.8)	16.9	10.5	72.9	83.8	97.0
EPS growth (%)					14.5	14.8	15.8	
PE (x)					35.2	30.7	26.5	
EV/EBITDA (x)					22.7	19.4	16.9	
PBV (x)					7.4	6.1	5.1	
RoE (%)					22.9	21.7	20.9	
RoCE (%)					17.3	17.1	16.9	

Source: Company, Centrum Broking

Result Update

India I Chemicals

10 May, 2023

ADD

Price: Rs2,571

Target Price: Rs2,895

Forecast return: 13%

Market Data

Bloomberg:	SRF IN
52 week H/L:	2,865/2,002
Market cap:	Rs762.2bn
Shares Outstanding:	296.4mn
Free float:	45.9%
Avg. daily vol. 3mth:	519,029
Source: Bloomberg	

Changes in the report

Rating:	ADD, changed from BUY earlier
Target price:	Rs2,895; Up 13.8% from Rs2,543
EPS:	FY24E: Rs83.8; up 2.1% FY25E: Rs97.0; down 4.0%

Source: Centrum Broking

Shareholding pattern

	Mar-23	Dec-22	Sep-22	Jun-22
Promoter	50.5	50.5	50.5	50.7
FII	18.5	18.3	19.2	19.2
DII	13.7	13.8	13.3	9.4
Public/other	17.3	17.3	16.9	20.7

Source: BSE

Centrum estimates vs Actual results

YE Mar (Rs mn)	Centrum Q4FY23	Actual Q4FY23	Variance (%)
Revenue	37,296	37,781	1.3
EBITDA	9,294	9,316	0.2
EBITDA margin %	24.9	24.7	(20bps)
Adj. PAT	5,406	5,625	4.0

Source: Bloomberg, Centrum Broking



Rohit Nagraj

Research Analyst, Chemicals
+91-022-4215 9645
rohit.nagraj@centrum.co.in



Jay Bharat Trivedi

Research Associate, Chemicals
+91-022-4215 9201
jay.trivedi@centrum.co.in

Thesis Snapshot

Estimate revision

YE Mar (Rs mn)	FY24E New	FY24E Old	% chg	FY25E New	FY25E Old	% chg
Revenue	1,63,133	1,69,396	(3.7)	1,87,534	1,95,203	(3.9)
EBITDA	41,208	41,051	0.4	47,074	49,585	(5.1)
PBT	32,453	31,777	2.1	37,578	39,145	(4.0)
Adj. PAT	24,827	24,309	2.1	28,747	29,946	(4.0)

Source: Centrum Broking

SRF versus NIFTY 50

	1m	6m	1 year
SRF IN	7.6	10.0	21.7
NIFTY 50	3.3	(0.2)	13.3

Source: Bloomberg, NSE

Key assumptions

Y/E Mar	FY24E	FY25E
Segment rev. growth		
Technical textiles business (TTB)	(0.5)	0.7
Chemicals business (CB)	20.6	21.3
Packaging films business (PFB)	(3.4)	10.0
Segment EBITDA margin (%)		
Technical textiles business (TTB)	16.5	17.0
Chemicals business (CB)	35.0	32.0
Packaging films business (PFB)	14.0	17.0


Source: Centrum Broking

Valuations


We estimate FY22-25E Revenue/ EBITDA/ PAT CAGR of 14.7%/ 14.9%/ 15.0%. The stock is trading at 30.7x/ 26.5x FY24E/ FY25E EPS of Rs83.8/ Rs97.0. Since our last update the stock has moved up by ~18%. We have valued SRF using SOTP methodology downgrade our rating to ADD with a revised TP of Rs2,895 (earlier Rs2,543)

SOTP	FY25E EBITDA	EV/ EBITDA (x)	Value (Rs mn)
Technical textiles business (TTB)	3,226	10	32,261
Chemicals business (CB)	34,689	22	7,63,152
Packaging films business (PFB)	9,365	10	93,651
Others	539	8	4,312
Net Debt			35,274
Implied value (Rs mn)			8,58,102
No. of shares			296
Target price (Rs)			2,895

P/E mean and standard deviation



EV/EBITDA mean and standard deviation



Source: Bloomberg, Centrum Broking

Peer comparison

Company	Mkt Cap (Rs bn)	CAGR (FY22-25E)				P/E (x)				EV/EBITDA (x)				ROE (%)			
		Sales	EBITDA	EPS	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY23E	FY24E	FY25E	FY24E	FY25E		
Aarti Industries	183.8	12.5	(0.9)	18.2	37.0	33.5	22.7	21.0	18.5	14.1	11.6	11.6	15.1				
Anupam Rasayan	121.9	31.9	30.7	29.2	35.2	30.7	26.5	22.7	19.4	16.9	22.9	21.7	20.9				
Atul	203.1	11.3	9.8	9.9	39.4	31.7	25.3	26.2	21.0	16.8	11.3	12.9	14.4				
Deepak Nitrite	267.0	13.7	12.4	14.2	29.9	19.7	16.8	19.7	13.3	11.3	23.8	28.3	25.7				
Dhanuka Agritech	30.1	13.1	12.3	10.3	14.7	13.0	11.4	11.4	9.4	8.1	21.3	21.8	21.6				
Galaxy Surfactants	88.8	6.9	8.8	8.9	24.0	27.7	25.3	16.1	17.7	16.1	20.8	15.6	15.1				
Gujarat Fluorochemicals	361.2	27.2	30.2	28.3	28.1	26.6	22.4	18.9	17.3	14.6	27.2	22.7	21.7				
Navin Fluorine	236.4	33.0	40.2	34.3	66.0	47.3	36.4	45.1	30.5	24.6	17.8	21.2	23.1				
PI Industries	523.3	20.5	23.6	25.3	36.8	33.4	28.0	28.1	25.2	20.8	19.0	17.9	18.3				
SRF	762.3	14.7	14.9	15.0	35.2	30.7	26.5	22.7	19.4	16.9	22.9	21.7	20.9				
UPL	519.3	15.3	12.4	19.3	15.0	13.0	10.6	6.9	6.1	5.2	13.1	13.1	14.4				
Vinati Organics	205.0	27.2	26.3	25.6	40.6	35.2	28.0	31.0	27.1	21.6	23.5	22.5	23.5				

Source: Company, Centrum Broking

Q4FY23 concall highlights

CB overall 20%+ growth in FY24E however margins to moderate, PFB margins to remain under pressure, marginal recovery in TTB margins

Financials – Depreciation and interest to go up in FY24E

- FY24E Capex – Rs25bn, Rs12-14bn cash capex on ongoing projects
- Debt – less than one EBITDA
- FY23 CB margins expansion – For both specchem and fluorochemicals
- No one-offs in PFB segment in Q4
- Average cost of debt by end-FY23 – 4.5%
- Looking for land for expansion, proximity to Dahej plant
- Depreciation and interest to grow substantially in FY24E

FY23 operating rates – PFB and TTB affected in FY23

- SpecChem – Dedicated plants always full, always some capacity available in MPPs, new projects commissioned in FY23 currently in ramp up
- Fluorochemicals – 75-85% HFCs, new chloromethanes plant commissioned in October 2022 ramping up currently, older plant operating at full levels
- PFB – 92-95%, Hungary – 69-70%, exit at 65%
- TTB – 75-76%

Chemicals (Specialty Chemicals) – 20%+ growth for FY24E for overall CB including SpecChem + Refgas

- FY23 revenues – ~Rs42bn, up ~35% YoY
- FY24E – 20%+ growth for FY24E
- RoCE may moderate from current levels of ~32% as new projects come in, happy with 25-27% RoCE projects
- Some moderation in margins going ahead based on Q4 perspective
- 80-85% innovator driven business
- Not seeing any demand reduction from any customers
- Focus on scale up of commissioned projects in FY24E
- New commissioning in FY24E – 7 plants in specialty, 3 in fluorochemicals
- Strong capex intensity to continue
- Growing demand for new products
- Capitalising on new AI opportunities, significant number of projects with innovators – 7-8 active intermediate in 2 years for agro market, largely for patented products, both fluorine/ non-fluorine based, in the process of getting contracted, very good visibility to commercialise in next two years
- Focus on pharma – To enter into CDMO space through organic or inorganic route, to become a large player in pharma, it can be capabilities/ R&D or capacities or market entry
- Dymel capacity – 2,000-2,200MT, can go up to 2,500MT, currently using at 1,400MT
- Pricing premium on Dymel over HFC134a – USD4-10
- AIs – 12-15% contribution
- Eyeing on import substitution products in next leg of chemicals

Chemicals (Fluorochemicals) – Refgas demand pressure in Q1, to pick up from Q2

- FY23 revenues – ~Rs32bnr, up ~54% YoY
- FY24E – 20%+ growth for FY24E
- Refgas – Focus on domestic market in Q1, to remain under pressure due to cool summer, however temporary, to make up for loss in subsequent year, US focus in subsequent 2 quarters
- Eyeing refgas exports to Middle-East markets in Q2
- PTFE – Commissioning by end-May/ June, confident of PFOA free process/ capacity, expect to operate at 50% capacity utilisation in Q3/ Q4, initial focus on ramping up the capacity, 12 months to start specialty grade post capacity ramp up
- HFO – More details post ground work is complete, non-infringing process, remain confident
- HFCs in US – 30% cut from January 2024 GWP equitant based for the next five years, production to be cut too, US to remain net importer of HFCs
- 15,000MT R32 plant – To commercialise in Jun/ Jul, product availability from Aug/ Sept., to be ramped up to 70% utilisation in 12 months post commissioning and subsequent year 100%, eyeing ME markets
- PVDF, FEP, FKM – Battery, solar, auto, aerospace applications (rest as per earlier concall)
- Specialty fluoropolymers – Capacity 4,500MT, PFOA free technology, 0.8-1.2x asset turns, four years payback

Packaging Film Business (BOPET and BOPP Films) – Margins to remain under pressure in medium term

- Some capacity closures due to cash losses
- Margins bottomed out, to improve from hereon
- Hungary – Operating issues in FY23 due to energy, moderation in energy index, expect better performance in FY24E
- South Africa – 10-15% capacity enhancement through debottlenecking
- VAP sales came to rescue
- Aluminium foil – Project cost increase to improve quality and capacity, IRR still healthy despite project cost increase
- New lines have been ordered, however getting delayed, to put pressure
- Confident and cautiously optimistic on the segment

Technical Textiles Business (Tyre Cord Fabrics, Industrial Yarns, Belting Fabrics) – Flattish demand

- Slight improvement in NTCF demand, sustainable
- Focus on ramping up capacity in FY24E
- Focus on high end VAPs in belting fabrics
- Moderate growth in FY23

Q4FY23 snippets from presentation

Focus on new product launches in SpecChem, refgas demand to remain strong, PFB margins to remain under pressure in near term, flat demand in TTB

Chemicals (Specialty Chemicals) – Volume led growth from new products

- New products commercialized in FY23, SRF launched 6 new products, 4 in Agro and 2 in the Pharma segment
- Key products and their derivatives witnessed increased YoY sales in Q4
- Commissioned new plants during the year which will aid future volumes
- Several ongoing projects on track and likely to be commissioned in the near future
- Witnessed increased downstream customer demand for complex and advanced products, multiple AIs under discussion with various customers.
- **Market Trends** – Global agrochemical market witnessed healthy growth, leading to better sales of top agrochemical companies, prices for certain key RMs remained high, resulting in elevated production costs of some end products, however, some softening witnessed during the latter part of the year, usage of Fungicides and Herbicides is on the rise, resulting in overall healthy growth
- **Outlook specialty chemicals** – Recently capitalised PIP plant ramp up likely to be strong, Complex products and AIs witnessing significant traction with customers, Fungicides and Herbicides continue to show growth, continued focus on launch of new products, continue expanding portfolio of RM suppliers to de risk availability

Chemicals (Fluorochemicals) – Some impact on HFC volumes in Q1FY24E likely due to a weak summer season, likely to be transitory

- **Strong Q4** – Strong demand for Ref Gases; NPR's of major HFC's remained strong, record sales achieved for Dymel® HFA 134a/P, with an expanded geographical footprint across 20+ countries
- Commissioned several new plants during the year – CMS2, CPP, and CaCl2
- Continued focus on ramping up operations in FY24E and commissioning of ongoing projects – PTFE facility commissioning expected in Q1FY23, samples being produced for the market, PX-1/PX-2 progressing as per plan
- Business to focus on building export portfolio in CMS to offset margin pressure due to domestic market slow down and oversupply situation
- **Market Trends** – Global demand outlook for refrigerant gas remains strong and sustainable, healthy opportunities in key markets of India, USA, and Middle East, RM prices and supply chain restrictions continue to be challenges, **some impact on HFC volumes in Q1FY24E likely due to a weak summer season, likely to be transitory**
- **Outlook Fluorochemicals** – Positive trend is likely to continue - demand in the refrigerants segment is expected to remain healthy in the near to medium term, focus on expanding in new markets / geographies and product offerings, ramping up sales from refrigerants, blends and industrial solvents, commissioning of PTFE and getting product approvals in place to remain in focus, strong focus on effective resource utilization

Packaging Film Business (BOPET and BOPP Films) – Margin pressure to continue in medium term, aluminium foil project on track

- Business continued to face headwinds including margin pressure due to significant supply addition, global demand slowdown, and steep energy costs in Europe
- To navigate through the uncertain times, SRF expanded its customer footprint and focused on VAP sales
- Aluminium Foil project progressing as per plan, albeit with some cost increase; higher output, quality and product portfolio being key reasons. SRF to become a solution provider of the three major substrates—BOPET, BOPP and Aluminium Foil
- 10 new products commercialised during the year (4 in BOPET and 6 in BOPP)
- Volume gains from debottlenecked South African unit capacity likely to aid operational efficiencies
- **Market Trends** – FY24E expected to see continued pressure on margins, energy costs moderating in Europe, global suppliers with multi locational facilities and customer relationships likely to witness positive traction
- **Outlook** – Aluminium foil project progressing as per plan, focus on value-added products both in BOPP and BOPET, Hungary expected to perform better in the ensuing quarters, demand supply mismatch and pressure on margins expected to continue at least in the medium term, some industry players witnessing cash losses, delay / cancellations of ordered lines likely to play out, continued focus on increasing pace of R&D efforts, sustainability initiatives and cost optimisation

Technical Textiles Business (Tyre Cord Fabrics, Industrial Yarns, Belting Fabrics) – NTCF witnessing revival

- Demand for Nylon Tyre Cord Fabric remained subdued during Q4
- Belting Fabric delivered higher YoY sales
- Improvement in demand for Polyester Industrial Yarn with key drivers being geotextiles and seat belts
- Focus on high-end VAP sales giving positive results
- Enhanced focus on renewable energy, with a significant percentage of the energy requirements being met by green sources
- **Market Trends** – Trends showing slight improvement in demand for Nylon Tyre Cord Fabric, Demand for Belting Fabrics is expected to remain healthy with enhanced focus on infrastructural development
- **Outlook** – Higher operating leverage and cost optimization by capacity rationalization across various plants, demand in NTCF witnessing revival, augurs well for the near future, PIY and NIY sales witnessing positive trends, other sub-segments of TTB expected to make a significant contribution to the overall performance

Others (Coated and Laminated Fabrics) – Margins to remain under pressure

- **Coated fabrics** – Recorded its highest ever domestic sales and EBITDA due to steady demand and a robust order book, witnessed improved demand in all categories, with healthy contribution from VAPs
- **Laminated fabrics** – SRF maintained its price leadership in Q4 by selling full capacity, margins in mass signage application were subdued and expected to remain under pressure due to oversupply in the market

Exhibit 1: Quarterly Financials

Quarterly (Rs mn)	Q4FY21	Q1FY22	Q2FY22	Q3FY22	Q4FY22	Q1FY23	Q2FY23	Q3FY23	Q4FY23	YoY (%)	QoQ (%)
Revenues	26,077	26,994	28,390	33,459	35,494	38,947	37,278	34,697	37,781	6.4	8.9
Q-o-Q gr. (%)	21.5	3.5	5.2	17.9	6.1	9.7	(4.3)	(6.9)	8.9		
Raw Mat. Cons.	12,849	13,023	14,157	15,965	15,769	17,826	18,904	15,616	18,817	19.3	20.5
% of net sales	49.3	48.2	49.9	47.7	44.4	45.8	50.7	45.0	49.8		
Purchase of prod.	189	294	144	450	868	751	626	1,328	67	(92.3)	(95.0)
% of net sales	0.7	1.1	0.5	1.3	2.4	1.9	1.7	3.8	0.2		
Power, fuel, and water	2,097	2,318	2,638	3,002	3,398	4,103	3,737	3,443	3,440	1.2	(0.1)
% of net sales	16.3	17.8	18.6	18.8	21.5	23.0	19.8	22.0	18.3		
Employee Costs	1,753	1,820	1,777	2,068	2,135	1,942	1,953	2,102	2,142	0.3	1.9
% of net sales	6.7	6.7	6.3	6.2	6.0	5.0	5.2	6.1	5.7		
Exchange currency fluctuation loss / (gain)	-91	-72	-206	-335	-114	249	361	150	280	(345.7)	86.2
% of net sales	(0.7)	(0.6)	(1.5)	(2.1)	(0.7)	1.4	1.9	1.0	1.5		
Others	2,846	2,895	3,130	3,496	3,958	4,126	4,007	3,723	3,719	(6.1)	(0.1)
% of net sales	10.9	10.7	11.0	10.4	11.2	10.6	10.7	10.7	9.8		
EBITDA	6,433	6,716	6,750	8,814	9,480	9,950	7,691	8,335	9,316	(1.7)	11.8
Q-o-Q growth (%)	13.6	4.4	0.5	30.6	7.6	5.0	(22.7)	8.4	11.8		
EBITDA Margin (%)	24.7	24.9	23.8	26.3	26.7	25.5	20.6	24.0	24.7		
Dep. & Amor.	1,185	1,230	1,303	1,324	1,316	1,307	1,393	1,507	1,546	17.5	2.6
EBIT	5,249	5,486	5,447	7,490	8,164	8,642	6,298	6,829	7,770	(4.8)	13.8
Interest exp.	262	275	234	294	357	325	445	620	659	84.6	6.4
Other Income	130	138	111	107	72	99	327	100	223	208.9	123.1
EBT	5,117	5,349	5,324	7,303	7,879	8,416	6,181	6,309	7,334	(6.9)	16.2
Provision for tax	1,302	1,396	1,500	2,247	1,996	2,336	1,693	1,293	1,790	(10.3)	38.5
Eff. tax rate (%)	25.4	26.1	28.2	30.8	25.3	27.8	27.4	20.5	24.4		
Net Profit	3,815	3,953	3,825	5,055	5,883	6,080	4,488	5,017	5,544	(5.8)	10.5
Q-o-Q gr. (%)	18.0	3.6	(3.2)	32.2	16.4	3.3	(26.2)	11.8	10.5		
PAT Margin (%)	14.6	14.6	13.4	15.1	16.5	15.6	11.9	14.4	14.6		
Segments revenue (₹ mn)											
Technical textile business (TTB)	4,006	4,929	5,579	5,378	4,967	5,710	4,662	4,259	4,307	(13.3)	1.1
Chemicals Business (CB)	11,526	11,137	11,264	14,283	15,725	17,224	18,302	17,566	21,017	33.7	19.6
Packaging film business (PFB)	9,795	10,413	10,717	12,760	13,902	14,960	13,310	12,027	11,531	(17.1)	(4.1)
Others	777	536	863	900	934	1,056	1,004	923	943	1.0	2.1
Total	26,104	27,015	28,423	33,321	35,527	38,951	37,278	34,776	37,797	6.4	8.7
EBIT											
Technical textile business EBIT	728	1,337	1,328	1,135	914	1,162	629	342	484	(47.1)	41.5
% EBIT	18.2	27.1	23.8	21.1	18.4	20.4	13.5	8.0	11.2		
Chemicals Business EBIT	2,752	2,223	2,511	4,192	5,043	5,202	5,173	5,639	7,393	46.6	31.1
% EBIT	23.9	20.0	22.3	29.4	32.1	30.2	28.3	32.1	35.2		
Packaging film business EBIT	2,186	2,368	1,795	2,542	2,758	2,952	1,014	1,186	410	(85.2)	(65.5)
% EBIT	22.3	22.7	16.7	19.9	19.8	19.7	7.6	9.9	3.6		
Others EBIT	88	19	58	86	41	68	76	91	113	177.0	24.0
% EBIT	11.3	3.5	6.7	9.5	4.4	6.4	7.6	9.9	12.0		
Total EBIT	5,753	5,947	5,692	7,955	8,757	9,384	6,892	7,259	8,399	(4.1)	15.7
% EBIT	22.0	22.0	20.0	23.9	24.6	24.1	18.5	20.9	22.2		

Source: Company, Centrum Broking

P&L					
YE Mar (Rs mn)	FY21A	FY22A	FY23A	FY24E	FY25E
Revenues	82,954	123,128	145,918	162,263	186,614
Operating Expense	40,189	60,669	73,935	79,124	92,191
Employee cost	6,214	7,800	8,138	9,359	10,763
Others	16,264	24,835	31,337	33,442	37,507
EBITDA	21,333	31,032	35,292	41,208	47,074
Depreciation & Amortisation	4,531	5,172	5,753	6,732	7,970
EBIT	16,803	25,860	29,539	34,476	39,103
Interest expenses	1,340	1,159	2,048	2,832	2,537
Other income	664	1,155	749	809	1,012
PBT	16,127	25,856	28,240	32,453	37,578
Taxes	4,144	6,966	6,617	7,627	8,831
Effective tax rate (%)	25.7	26.9	23.4	23.5	23.5
PAT	11,983	18,889	21,623	24,827	28,747
Minority/Associates	0	0	0	0	0
Recurring PAT	11,983	18,889	21,623	24,827	28,747
Extraordinary items	0	0	0	0	0
Reported PAT	11,983	18,889	21,623	24,827	28,747
Ratios					
YE Mar	FY21A	FY22A	FY23A	FY24E	FY25E
Growth (%)					
Revenue	17.5	48.4	18.5	11.2	15.0
EBITDA	46.6	45.5	13.7	16.8	14.2
Adj. EPS	30.8	57.6	14.5	14.8	15.8
Margins (%)					
Gross	52.8	51.7	51.2	51.8	51.1
EBITDA	25.4	25.0	23.7	25.3	25.1
EBIT	20.0	20.8	19.9	21.1	20.9
Adjusted PAT	14.3	15.2	14.5	15.2	15.3
Returns (%)					
ROE	20.3	24.5	22.9	21.7	20.9
ROCE	14.4	18.0	17.3	17.1	16.9
ROIC	12.4	14.9	14.8	15.3	15.4
Turnover (days)					
Gross block turnover ratio (x)	0.9	1.2	1.2	1.1	1.1
Debtors	47	45	44	43	43
Inventory	121	108	109	108	104
Creditors	122	111	107	109	106
Net working capital	59	77	73	73	77
Solvency (x)					
Net debt-equity	0.4	0.4	0.4	0.3	0.2
Interest coverage ratio	15.9	26.8	17.2	14.6	18.6
Net debt/EBITDA	1.2	1.0	1.1	0.9	0.7
Per share (Rs)					
Adjusted EPS	40.4	63.7	72.9	83.8	97.0
BVPS	231.3	289.0	348.4	422.1	507.4
CEPS	278.8	81.2	92.4	106.5	123.9
DPS	23.9	7.1	7.2	10.1	11.6
Dividend payout (%)	11.8	11.2	9.9	12.0	12.0
Valuation (x)					
P/E	63.6	40.3	35.2	30.7	26.5
P/BV	11.1	8.9	7.4	6.1	5.1
EV/EBITDA	37.0	25.6	22.7	19.4	16.9
Dividend yield (%)	0.9	0.3	0.3	0.4	0.5

Source: Company, Centrum Broking

Balance sheet					
YE Mar (Rs mn)	FY21A	FY22A	FY23A	FY24E	FY25E
Equity share capital	603	2,974	2,974	2,974	2,974
Reserves & surplus	67,962	82,679	100,296	122,144	147,441
Shareholders fund	68,564	85,654	103,271	125,118	150,416
Minority Interest	0	0	0	0	0
Total debt	29,307	35,394	43,541	43,541	43,541
Non Current Liabilities	1,507	3,402	3,901	3,901	3,901
Def tax liab. (net)	3,862	6,775	8,092	8,092	8,092
Total liabilities	103,240	131,224	158,805	180,652	205,950
Gross block	94,172	104,017	125,744	150,744	177,244
Less: acc. Depreciation	(19,200)	(23,512)	(29,265)	(35,901)	(43,772)
Net block	74,972	80,505	96,479	114,843	133,471
Capital WIP	7,723	16,716	24,055	24,055	24,055
Net fixed assets	83,825	98,416	121,681	140,000	158,579
Non Current Assets	5,857	6,650	7,886	7,886	7,886
Investments	42	42	42	42	42
Inventories	14,658	21,385	22,743	24,177	28,170
Sundry debtors	12,746	17,925	17,856	20,392	23,442
Cash & Cash Equivalents	2,820	4,594	6,165	8,267	11,934
Loans & advances	112	88	110	110	110
Other current assets	9,053	8,553	10,876	10,876	10,876
Trade payables	15,852	20,964	22,313	24,855	28,847
Other current liab.	10,116	5,505	6,349	6,349	6,349
Provisions	87	74	79	79	79
Net current assets	13,335	26,001	29,009	32,538	39,256
Total assets	103,240	131,224	158,805	180,652	205,950
Cashflow					
YE Mar (Rs mn)	FY21A	FY22A	FY23A	FY24E	FY25E
Profit Before Tax	16,127	25,856	28,240	32,453	37,578
Depreciation & Amortisation	4,531	5,172	5,753	6,732	7,970
Net Interest	1,340	1,159	2,048	2,832	2,537
Net Change – WC	(3,911)	(12,067)	515	(1,427)	(3,050)
Direct taxes	(3,526)	(6,323)	(6,617)	(7,627)	(8,831)
Net cash from operations	13,896	12,643	29,190	32,154	35,192
Capital expenditure	(12,898)	(18,885)	(29,019)	(25,050)	(26,550)
Acquisitions, net	0	0	0	0	0
Investments	(2,140)	958	(1,733)	0	0
Others	664	1,155	749	809	1,012
Net cash from investing	(14,375)	(16,772)	(30,003)	(24,241)	(25,538)
FCF	(479)	(4,129)	(812)	7,913	9,654
Issue of share capital	7	0	0	0	0
Increase/(decrease) in debt	(3,364)	6,086	8,147	0	0
Dividend paid	(1,413)	(2,119)	(2,134)	(2,979)	(3,450)
Interest paid	(1,340)	(1,159)	(2,048)	(2,832)	(2,537)
Others	6,716	3,006	(1,666)	0	0
Net cash from financing	607	5,814	2,299	(5,811)	(5,986)
Net change in Cash	128	1,685	1,486	2,102	3,668

Source: Company, Centrum Broking

Disclaimer

Centrum Broking Limited ("Centrum") is a full-service, Stock Broking Company and a member of The Stock Exchange, Mumbai (BSE) and National Stock Exchange of India Ltd. (NSE). Our holding company, Centrum Capital Ltd, is an investment banker and an underwriter of securities. As a group Centrum has Investment Banking, Advisory and other business relationships with a significant percentage of the companies covered by our Research Group. Our research professionals provide important inputs into the Group's Investment Banking and other business selection processes.

Recipients of this report should assume that our Group is seeking or may seek or will seek Investment Banking, advisory, project finance or other businesses and may receive commission, brokerage, fees or other compensation from the company or companies that are the subject of this material/report. Our Company and Group companies and their officers, directors and employees, including the analysts and others involved in the preparation or issuance of this material and their dependants, may on the date of this report or from, time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. Centrum or its affiliates do not own 1% or more in the equity of this company. Our sales people, dealers, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. We may have earlier issued or may issue in future reports on the companies covered herein with recommendations/information inconsistent or different those made in this report. In reviewing this document, you should be aware that any or all of the foregoing, among other things, may give rise to or potential conflicts of interest. We and our Group may rely on information barriers, such as "Chinese Walls" to control the flow of information contained in one or more areas within us, or other areas, units, groups or affiliates of Centrum. Centrum or its affiliates do not make a market in the security of the company for which this report or any report was written. Further, Centrum or its affiliates did not make a market in the subject company's securities at the time that the research report was published.

This report is for information purposes only and this document/material should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. This document does not solicit any action based on the material contained herein. It is for the general information of the clients of Centrum. Though disseminated to clients simultaneously, not all clients may receive this report at the same time. Centrum will not treat recipients as clients by virtue of their receiving this report. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Similarly, this document does not have regard to the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The securities discussed in this report may not be suitable for all investors. The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. Persons who may receive this document should consider and independently evaluate whether it is suitable for his/ her/their particular circumstances and, if necessary, seek professional/financial advice. Any such person shall be responsible for conducting his/her/their own investigation and analysis of the information contained or referred to in this document and of evaluating the merits and risks involved in the securities forming the subject matter of this document.

The projections and forecasts described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. Projections and forecasts are necessarily speculative in nature, and it can be expected that one or more of the estimates on which the projections and forecasts were based will not materialize or will vary significantly from actual results, and such variances will likely increase over time. All projections and forecasts described in this report have been prepared solely by the authors of this report independently of the Company. These projections and forecasts were not prepared with a view toward compliance with published guidelines or generally accepted accounting principles. No independent accountants have expressed an opinion or any other form of assurance on these projections or forecasts. You should not regard the inclusion of the projections and forecasts described herein as a representation or warranty by or on behalf of the Company, Centrum, the authors of this report or any other person that these projections or forecasts or their underlying assumptions will be achieved. For these reasons, you should only consider the projections and forecasts described in this report after carefully evaluating all of the information in this report, including the assumptions underlying such projections and forecasts.

The price and value of the investments referred to in this document/material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. Future returns are not guaranteed and a loss of original capital may occur. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Centrum does not provide tax advice to its clients, and all investors are strongly advised to consult regarding any potential investment. Centrum and its affiliates accept no liabilities for any loss or damage of any kind arising out of the use of this report. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk. Certain transactions including those involving futures, options, and other derivatives as well as non-investment-grade securities give rise to substantial risk and are not suitable for all investors. Please ensure that you have read and understood the current risk disclosure documents before entering into any derivative transactions.

This report/document has been prepared by Centrum, based upon information available to the public and sources, believed to be reliable. No representation or warranty, express or implied is made that it is accurate or complete. Centrum has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The opinions expressed in this document/material are subject to change without notice and have no obligation to tell you when opinions or information in this report change.

This report or recommendations or information contained herein do/does not constitute or purport to constitute investment advice in publicly accessible media and should not be reproduced, transmitted or published by the recipient. The report is for the use and consumption of the recipient only. This publication may not be distributed to the public used by the public media without the express written consent of Centrum. This report or any portion hereof may not be printed, sold or distributed without the written consent of Centrum.

The distribution of this document in other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Neither Centrum nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information.

This document does not constitute an offer or invitation to subscribe for or purchase or deal in any securities and neither this document nor anything contained herein shall form the basis of any contract or commitment whatsoever. This document is strictly confidential and is being furnished to you solely for your information, may not be distributed to the press or other media and may not be reproduced or redistributed to any other person. The distribution of this report in other jurisdictions may be restricted by law and persons into whose possession this report comes should inform themselves about, and observe any such restrictions. By accepting this report, you agree to be bound by the foregoing limitations. No representation is made that this report is accurate or complete.

The opinions and projections expressed herein are entirely those of the author and are given as part of the normal research activity of Centrum Broking and are given as of this date and are subject to change without notice. Any opinion estimate or projection herein constitutes a view as of the date of this report and there can be no assurance that future results or events will be consistent with any such opinions, estimate or projection.

This document has not been prepared by or in conjunction with or on behalf of or at the instigation of, or by arrangement with the company or any of its directors or any other person. Information in this document must not be relied upon as having been authorized or approved by the company or its directors or any other person. Any opinions and projections contained herein are entirely those of the authors. None of the company or its directors or any other person accepts any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith.

Centrum and its affiliates have not managed or co-managed a public offering for the subject company in the preceding twelve months. Centrum and affiliates have not received compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for service in respect of public offerings, corporate finance, debt restructuring, investment banking or other advisory services in a merger/acquisition or some other sort of specific transaction.

As per the declarations given by them, Mr. Rohit Nagraj & Mr. Jay Bharat Trivedi, research analyst and and/or any of their family members do not serve as an officer, director or any way connected to the company/companies mentioned in this report. Further, as declared by them, they are not received any compensation from the above companies in the preceding twelve months. They do not hold any shares by them or through their relatives or in case if holds the shares then will not to do any transactions in the said scrip for 30 days from the date of release such report. Our entire research professionals are our employees and are paid a salary. They do not have any other material conflict of interest of the research analyst or member of which the research analyst knows of has reason to know at the time of publication of the research report or at the time of the public appearance.

While we would endeavour to update the information herein on a reasonable basis, Centrum, its associated companies, their directors and employees are under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Centrum from doing so.

Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or Centrum policies, in circumstances where Centrum is acting in an advisory capacity to this company, or any certain other circumstances.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject Centrum Broking Limited or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market.

Ratings definitions

Our ratings denote the following 12-month forecast returns:

Buy – The stock is expected to return above 15%.

Add – The stock is expected to return 5-15%.

Reduce – The stock is expected to deliver -5+5% returns.

Sell – The stock is expected to deliver <-5% returns.

SRF Ltd



Source: Bloomberg

Disclosure of Interest Statement

1 Business activities of Centrum Broking Centrum Broking Limited (hereinafter referred to as "CBL") is a registered member of NSE (Cash, F&O and Currency Derivatives Segments), MCX-SX (Currency Derivatives Segment) and BSE (Cash segment), Depository Participant of CDSL and a SEBI registered Portfolio Manager.	
2 Details of Disciplinary History of CBL	CBL has not been debarred/ suspended by SEBI or any other regulatory authority from accessing /dealing in securities market.
3 Registration status of CBL:	CBL is registered with SEBI as a Research Analyst (SEBI Registration No. INH000001469)

SRF Ltd

4 Whether Research analyst's or relatives' have any financial interest in the subject company and nature of such financial interest	No
5 Whether Research analyst or relatives have actual / beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the document.	No
6 Whether the research analyst or his relatives has any other material conflict of interest	No
7 Whether research analyst has received any compensation from the subject company in the past 12 months and nature of products / services for which such compensation is received	No
8 Whether the Research Analyst has received any compensation or any other benefits from the subject company or third party in connection with the research report	No
9 Whether Research Analysts has served as an officer, director or employee of the subject company	No
10 Whether the Research Analyst has been engaged in market making activity of the subject company.	No
11 Whether it or its associates have managed or co-managed public offering of securities for the subject company in the past twelve months;	No
12 Whether it or its associates have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;	No
13 Whether it or its associates have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;	No

Member (NSE and BSE). Member MSEI (Inactive)**Single SEBI Regn. No.: INZ000205331****Depository Participant (DP)**

CDSL DP ID: 120 – 12200

Single SEBI Regn. No.: IN-DP-537-2020

PORTFOLIO MANAGER

SEBI REGN NO.: INP000004383

Research Analyst

SEBI Registration No. INH000001469

Mutual Fund Distributor
AMFI REGN No. ARN- 147569**Website:** www.centrumbroking.com
Investor Grievance Email ID: investor.grievances@centrum.co.in**Compliance Officer Details:**

Ajay S Bendkhale

(022) 4215 9000/9023; Email ID: compliance@centrum.co.in

Centrum Broking Ltd. (CIN :U67120MH1994PLC078125)**Registered and Corporate Office:**Level -9, Centrum House, C.S.T. Road,
Vidyanagari Marg, Kalina,
Santacruz (East) Mumbai – 400098
Tel.: - +91 22 4215 9000